Coloplast A/S engages in the developing, manufacture, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.
How did CLPBY's recent EPS compare to expectations?
The most recent EPS for Coloplast A/S is $6.2, beating expectations of $6.1.
How did Coloplast A/S CLPBY's revenue perform in the last quarter?
Coloplast A/S revenue for the last quarter is $6.2
What is the revenue estimate for Coloplast A/S?
According to 10 of Wall street analyst, the revenue estimate of Coloplast A/S range from $7.73B to $7.07B
What's the earning quality score for Coloplast A/S?
Coloplast A/S has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Coloplast A/S report earnings?
Coloplast A/S next earnings report is expected in 2026-05-07
What are Coloplast A/S's expected earnings?
Coloplast A/S expected earnings is $7.22B, according to wall-street analysts.
Did Coloplast A/S beat earnings expectations?
Coloplast A/S recent earnings of $7.04B does not beat expectations.
